Referencemedlemsstaten og de berørte medlemsstater afviste type II- ændringen med den begrundelse, at det samlede benefit/ risk- forhold var negativt for indikationen initial vedligeholdelsesbehandling.
The RMS and CMSs rejected the type II variation based on the grounds that the overall risk/ benefit was unfavourable for the initial maintenance therapy indication.